TY - JOUR T1 - International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update JF - Pharmacological Reviews JO - Pharmacol Rev SP - 1 LP - 34 DO - 10.1124/pr.110.003285 VL - 63 IS - 1 AU - Bertil B. Fredholm AU - Adriaan P. IJzerman AU - Kenneth A. Jacobson AU - Joel Linden AU - Christa E. Müller Y1 - 2011/03/01 UR - http://pharmrev.aspetjournals.org/content/63/1/1.abstract N2 - In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major changes in the recommendations. However, there have been so many other developments that an update is needed. The fact that the structure of one of the adenosine receptors has recently been solved has already led to new ways of in silico screening of ligands. The evidence that adenosine receptors can form homo- and heteromultimers has accumulated, but the functional significance of such complexes remains unclear. The availability of mice with genetic modification of all the adenosine receptors has led to a clarification of the functional roles of adenosine, and to excellent means to study the specificity of drugs. There are also interesting associations between disease and structural variants in one or more of the adenosine receptors. Several new selective agonists and antagonists have become available. They provide improved possibilities for receptor classification. There are also developments hinting at the usefulness of allosteric modulators. Many drugs targeting adenosine receptors are in clinical trials, but the established therapeutic use is still very limited. ER -